NPM1 and acute myeloid leukemia: Thus, our results may explain, at least in part, the better prognosis and response to chemotherapy treatment of AML patients carrying the NPM1c+ mutation, which causes exclusion of NPM1 from the nucleus, leading to a polη deficiency, and therefore more effective killing of the leukaemic cells by drugs such as araC.